Abstract
Introduction

45
Bacillus anthracis is the bacterium that is the causative agent of anthrax, the zoonotic 46 disease and bioterrorism threat. The virulence of this gram positive bacterium is mediated 47 through its poly-D-glutamic acid capsule (11) and its tripartite toxin, composed of protective 48 antigen (PA), lethal factor (LF), and edema factor (EF) (21, 35) . PA is the intermediary that 
85
The studies presented here had three goals. We sought to isolate antibodies (1) having 86 the ability to prevent EF-mediated edema and systemic infection, (2) that could potentially serve 87 as reagents in future diagnostics, and (3) that would be useful reagents for further molecular 88 studies of EF action. We present a panel of antibodies of nanomolar and subnanomolar affinity 89 that bind to epitopes on three different domains of EF. Some of these antibodies neutralize EF 90 activity in vitro and in vivo and have significant protective effects at sub-stoichiometric ratios to 91 toxin. Additionally, these antibodies are useful as laboratory reagents and could be utilized after 92 further development as a platform for diagnostic assays. 
117
Mouse immunization, hybridoma fusion, antibody expression, purification, and subtyping 118 Two Balb/cJ mice that were initially 10 weeks old were immunized subcutaneously (SC) 119 with EF (10 µg/100 µl in PBS, without adjuvant) five times, at 2-week intervals, followed by a 120 sixth and final immunization 4 weeks after the fifth immunization. 
172
Kinetic parameters of the purified antibodies were determined using the ProteOn XPR36.
173
Each antibody was immobilized on a GLC chip in 10 mM acetate buffer, pH 5, using standard 
211
Each separate membrane was then exposed to a different monoclonal antibody or the control mix 212 of polyclonal antisera to assess specificity of the primary antibody. MAb to EF were incubated 213 with the membranes at a concentration of 1.4 µg/ml (9.5 nM). PA, LF, and EF controls were 214 detected with polyclonal rabbit antisera developed in our laboratory and used at 1:1000 dilutions. Hepes, pH 7.3, was added and allowed to incubate for 1 h at 37 °C to allow EF synthesis of 228 cAMP (reaction conditions were chosen based upon several previous studies) (14, 17, 27) . Then 229 100 µl of Cisbio lysis buffer supplemented with 50 mM EDTA was added and cAMP levels 230 were assessed using the cAMP HiRange kit (Cisbio).
231
Spore preparation
232
Spores were prepared from Ames 35, the avirulent, nonencapsulated, toxigenic B.
233
anthracis strain (25) as previously described (13) . Briefly, bacteria were grown at 37 °C 234 overnight followed by 7 days at 28 °C on NBY sporulation agar (8 g nutrient broth, 3 g yeast 235 extract, 15 g agar per liter water), and were then monitored by microscopy to confirm that 236 sporulation was greater than 95%. Spore purification was accomplished through four cycles of 237 centrifugation followed by washing in sterile water, and were then subjected to heat treatment at However, most of the antibodies that were shown to bind to EF in this screen did so in both screening. Antibodies from a total of 82 subclones were then assessed for EF binding by SPR.
272
Of these, four antibodies were selected for further characterization because they had the lowest 273 apparent off-rates, which is usually the best indicator of high affinity.
274
Scale-up, purification, subtyping, and initial characterization The abilities of the MAb to detect EF on Western blots were assessed. Under the 300 conditions used, all antibodies detected EF bound on a membrane, and they did so without cross-301 reacting with LF or PA (Fig. 2) . Further studies by SPR and in RAW264.7 cells treated with 302 lethal toxin (LT, a combination of LF and PA) showed that the anti-EF antibodies had no 303 reactivity with PA or LF at the concentrations used in these studies (data not shown).
304
To assess the potential utility of these MAb in diagnostic assays, an EF capture assay was 305 constructed. Each antibody was coated onto EIA plates, and different concentrations of purified 306 EF were incubated in each well. Detection of the captured EF was based on the catalytic activity 307 of EF; cAMP levels generated by incubation in a reaction mixture with calmodulin, Mn
2+
, and 308 ATP were measured using a FRET-based time-resolved fluorescence assay (Fig. 3) exhibited marginal neutralizing activity at the concentrations tested.
322
To further characterize the protective effects of these antibodies, studies were performed To determine the efficacy of these anti-EF antibodies in an infection model, the MAb 336 were administered 10 min prior to subcutaneous spore challenge in forelimbs, and localized 337 edema was assessed at the site of injection 24 h later (Fig. 7A) . spores caused a highly significant shift in time to death relative to untreated controls. The 345 previously described chimpanzee anti-EF antibody EF13D (4) also significantly delayed time to 346 death (when used at 25 µg) while eliciting 50% survival (Fig. 7B) . Each of the three mouse 347 monoclonal antibodies was not protective when given alone at a dose of 25 µg (data not shown).
348
Median time to death for the PBS treated controls was 64 h and was significantly extended to 349 144 h for both EF13D and the combination of mouse monoclonal antibodies.
351
Discussion
352
We developed and characterized four MAb to EF, and showed that three of the four have catalytic C B domain, and helical domain), which further illustrates the previously described 366 diverse response of the mouse immune system to EF (22) .
367
Another goal in producing these antibodies was to create highly specific reagents that 368 could be used for molecular studies in future work. To that end, all antibodies were useful in a
369
Western blot analysis, and they were specific for EF and not cross-reactive with LF or PA. This 
